about
Current practices and reform proposals for the regulation of advanced medicinal products in CanadaInternational Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials.Soliciting strategies for developing cell-based reference materials to advance mesenchymal stromal cell research and clinical translation.Proceedings: international regulatory considerations on development pathways for cell therapies.Current concepts: the role of mesenchymal stem cells in the management of knee osteoarthritis.A Systematic Study of the Effect of Different Molecular Weights of Hyaluronic Acid on Mesenchymal Stromal Cell-Mediated ImmunomodulationNatural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model.Towards predictive models of stem cell fate.A Simplified Method for the Aspiration of Bone Marrow from Patients Undergoing Hip and Knee Joint Replacement for Isolating Mesenchymal Stem Cells and In Vitro ChondrogenesisOvercoming challenges to initiating cell therapy clinical trials in rapidly developing countries: India as a model.Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells.Bringing regenerative medicines to the clinic: the future for regulation and reimbursement.TLR3 or TLR4 Activation Enhances Mesenchymal Stromal Cell-Mediated Treg Induction via Notch Signaling.Supplementation-dependent differences in the rates of embryonic stem cell self-renewal, differentiation, and apoptosis.Mesenchymal stromal cells improve cardiac function and left ventricular remodeling in a heart transplantation model.Strategy for an abbreviated in-house qualification of a commercially available Rapid Microbiology Method (RMM) for canadian regulatory approval.OCT4 expression mediates partial cardiomyocyte reprogramming of mesenchymal stromal cells.Development and characterization of a new inbred transgenic rat strain expressing DsRed monomeric fluorescent protein.Donor mesenchymal stromal cells (MSCs) undergo variable cardiac reprogramming in vivo and predominantly co-express cardiac and stromal determinants after experimental acute myocardial infarction.Workshop to address gaps in regulation of minimally manipulated autologous cell therapies for homologous use in Canada.19F-perfluorocarbon-labeled human peripheral blood mononuclear cells can be detected in vivo using clinical MRI parameters in a therapeutic cell setting.Stage-specific differences in secretory profile of mesenchymal stromal cells (MSCs) subjected to early- vs late-stage OA synovial fluid.Synovial fluid monocyte/macrophage subsets and their correlation to patient-reported outcomes in osteoarthritic patients: a cohort studyLigand/Receptor Signaling Threshold (LIST) Model Accounts for gp130-Mediated Embryonic Stem Cell Self-Renewal Responses to LIF and HIL-6Recommendations for Regulating the Environmental Risk of Shedding for Gene Therapy and Oncolytic Viruses in CanadaMesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclatureMesenchymal stromal cell therapy: progress in manufacturing and assessments of potencyAnti-fibrotic mechanisms of exogenously-expanded mesenchymal stromal cells for fibrotic diseasesIron nanoparticle-labeled murine mesenchymal stromal cells in an osteoarthritic model persists and suggests anti-inflammatory mechanism of actionRecent progress on developing exogenous monocyte/macrophage-based therapies for inflammatory and degenerative diseasesBone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation
P50
Q26799720-2295A307-23FA-4422-BE8A-3E4E2E89570AQ30488740-5959B42B-85E5-4802-B1CC-122E9FFEFF43Q33637202-7C181690-C995-40B8-8DF3-968CEA21DD3FQ33975643-87BE7B79-8119-4566-AC57-4071E222EF20Q34747451-7D80F4FC-179F-436F-80B2-505576B172E7Q35906997-7FE0305E-3989-4289-B8DD-5DFB5DFF1E59Q36094697-2B80B5B2-48FE-4C85-8F66-8A348C407D4DQ36304569-E6A9789F-F41C-40D4-BEF9-B0D5C9530B30Q36615333-111F6D9B-E1FF-4B2C-8CF4-4798F010F6C1Q37052853-E3EB48D0-9417-4A3F-8DEC-0C91FD5F14AEQ37999098-B4AF7496-6A2C-460F-8703-36C2325F8D7FQ38632641-31CB1307-58A6-498F-A6B4-69A120286F5AQ39443690-2C03A888-CEB7-4949-8E91-24B8B6B7D04FQ40623756-F8CF5C8E-9BFA-44AA-8E5E-C3DC80D18338Q40669267-C74B3B1A-2CA2-456A-A088-B79AF78D0EEDQ46275805-7E8A447E-8B87-49CC-B48B-287FB08CDC1AQ47101037-6AC67E0D-856B-45F2-9726-B2EFF2FBB0A9Q47571873-2855FB61-D387-45C1-B624-0621ED778A55Q47573004-7F2C1EC3-253E-4DAF-8D7E-142BB4512D2EQ47614686-F39FDB69-86B1-49A2-AC88-A3EE34B92DA4Q48507624-B5378180-48D2-457E-8DE3-3879EF9477E9Q48921451-529224EA-CC40-49E8-9794-E8A6F075D664Q61446184-C2250A9A-B21D-4433-9D9E-228C8A6ED1F1Q62658874-1A566CD8-6F81-40F2-9851-1D5095E83AC1Q64106852-48E5C72F-50CE-47B0-835C-30F487EA492CQ90129658-3E8DD61E-C209-4BBD-9935-BD235F6FB2F4Q90354089-71F449E7-C172-49AD-854C-160D8F67076AQ91402772-44456FF1-C5FF-4C86-86C9-ACDE0939CF00Q91638697-276D21DC-1455-4368-AE1C-0DA082F3BBE1Q92366772-DA4EF85D-1BEB-427A-8151-ACC485F94367Q92965674-8E0EDEAC-F281-48D9-968E-EEC3563EFCFF
P50
description
researcher ORCID ID = 0000-0002-4552-0179
@en
wetenschapper
@nl
name
Sowmya Viswanathan
@ast
Sowmya Viswanathan
@en
Sowmya Viswanathan
@es
Sowmya Viswanathan
@nl
type
label
Sowmya Viswanathan
@ast
Sowmya Viswanathan
@en
Sowmya Viswanathan
@es
Sowmya Viswanathan
@nl
prefLabel
Sowmya Viswanathan
@ast
Sowmya Viswanathan
@en
Sowmya Viswanathan
@es
Sowmya Viswanathan
@nl
P106
P1153
57195144667
P31
P496
0000-0002-4552-0179